Racheal Ede

3 weeks ago | medcentral.com | Racheal Ede

A pair of recent studies examined the impact of common risk factors – sleep quality and smoking status – on kidney and cardiovascular disease in individuals at various stages of cardiovascular kidney metabolic syndrome. Sleep Quality May Amplify CKM SeverityIn a nationally representative cross-sectional study, people with moderate and high sleep quality had a 32% and 45% lower risk, respectively, of being in advanced stages of cardiovascular kidney metabolic (CKM) syndrome.

1 month ago | medcentral.com | Racheal Ede

Individuals with higher risk for cardiovascular‐kidney‐metabolic (CKM) syndrome also had a greater risk of cognitive decline, based on data from a 20‐year longitudinal study published in the Journal of the American Heart Association this month. Cardiovascular‐kidney‐metabolic (CKM) syndrome, a newly defined condition highlighting the interactions between chronic kidney disease, metabolic risk factors, and cardiovascular disease, is on the rise globally.

1 month ago | oncologynewscentral.com | Racheal Ede

Exposure to colibactin bacteria in early childhood was associated with early-onset colorectal cancer (EOCRC) as colibactin-induced mutations were 3.3 times more prevalent in individuals diagnosed before age 40, compared to those above 70, according to a global study. The growing incidence of early-onset colorectal cancer over the past two decades has raised significant questions about its underlying causes and specific risk factors.

1 month ago | medcentral.com | Racheal Ede

Exposure to colibactin bacteria in early childhood was associated with early-onset colorectal cancer (EOCRC) as colibactin-induced mutations were 3.3 times more prevalent in individuals diagnosed before age 40, compared to those above 70, according to a global study. The growing incidence of early-onset colorectal cancer over the past two decades has raised significant questions about its underlying causes and specific risk factors.

1 month ago | medcentral.com | Racheal Ede

New global consensus recommendations for the identification and treatment of high-risk metabolic dysfunction-associated steatotic liver disease(MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) have been published in the journal Gastroenterology. The increasing prevalence of MASLD and MASH has compelled several national and international societies to develop management guidelines.